New Journey(002219) 首创证券·2024-08-07 07:30Investment Rating - The report assigns a "Buy" rating to the company [1] Core Views - The company plans to repurchase shares at a price not exceeding RMB 2 74 per share with a total amount ranging from RMB 50 million to RMB 100 million The repurchased shares will be used to reduce registered capital [1] - The healthcare services sector has shown steady growth with a 5 62% increase in revenue to RMB 740 million in Q1 2024 New hospital constructions are progressing well with several projects expected to be operational by the end of 2024 [3] - The company's pharmaceutical sector achieved a 45 24% increase in revenue to RMB 121 million in Q1 2024 driven by the acquisition of Gansu Furen Pharmaceutical and the exploration of the "Duyiwei" brand's potential in the consumer market [3] - The company's share repurchase demonstrates confidence in future development and is expected to enhance earnings per share and shareholder returns [3] Financial Projections - Revenue is projected to grow from RMB 40 06 billion in 2024 to RMB 50 04 billion in 2026 with a compound annual growth rate (CAGR) of 11 6% [3] - Net profit attributable to the parent company is expected to increase significantly from RMB 143 million in 2024 to RMB 350 million in 2026 with growth rates of 362 7% 78 5% and 37 5% respectively [3] - The company's PE ratio is forecasted to decrease from 53 7 in 2024 to 21 9 in 2026 indicating improving valuation metrics [3] Business Development - The healthcare services sector is expected to benefit from both organic growth and external expansion The company is actively pursuing asset injections and has submitted materials to the Shenzhen Stock Exchange for a private placement [3] - The company's controlling shareholder manages nearly 30 secondary and above hospitals nationwide with a total of 20 000 beds which is approximately twice the scale of the listed company's assets [3] Financial Ratios - The company's gross margin is expected to improve from 30 1% in 2023 to 35 6% in 2026 while the net margin is projected to increase from 1 1% to 7 3% over the same period [4] - ROE is forecasted to rise from 1 4% in 2023 to 8 4% in 2026 reflecting enhanced profitability and efficiency [4]